Eventide Asset Management led a $116m Series B round in Korro Bio.

Eventide Asset Management, a Boston-based registered investment advisor, led a $116m Series B round in Korro Bio, an RNA editing company focused on the discovery and development of novel genetic medicines, with participation from Fidelity Management & Research Company, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital, Atlas Venture, NEA, Wu Capital, Qiming Venture Partners, Surveyor Capital (a Citadel company), Cormorant Asset Management, MP Healthcare Venture Management and Alexandria Venture Investments. "Our proprietary RNA editing platform redirects endogenous human editing, ADAR, with the ability to change a single base on RNA with high specificity and efficiency. The elegance of the approach is in its simplicity and enables us to not only repair mutations that cause genetically inherited diseases but also to modulate select proteins with high specificity in prevalent diseases. The Series B financing has expanded our strong syndicate of investors enabling us to execute on our vision of advancing our pipeline of novel gene editing candidates to the clinic for patients suffering from a broad spectrum of diseases," Ram Aiyar, Korro Bio CEO and President.